[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymph-node-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymph-node-dissection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,82,108,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100617637","radical-nephroureterectomy-with-vs-without-template-lymph-node-dissection-in-high-risk-upper-tract-urothelial-carcinoma-t-lnd-utuc-100617637",false,"NCT07321210","Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)","Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial","UTLUND","Inclusion Criteria:\n\n* Signed written informed consent form (ICF).\n* Age \\> 18 years at the time of ICF signing.\n* Clinical diagnosis of unilateral Upper Tract Urothelial Carcinoma (UTUC) by imaging (enhanced CT or MRI) and\u002For ureteroscopic biopsy\u002Furinary cytology, and scheduled to undergo Radical Nephroureterectomy (RNU).\n* Clinical assessment indicating that the tumor and regional lymph nodes are completely resectable, with at least one of the following high-risk features:\n\n  1. Locally advanced: Preoperative imaging assessed as cT2 stage or higher (i.e., tumor invades muscularis propria or deeper).\n  2. High-grade: Preoperative ureteroscopic biopsy pathology confirmed as high-grade urothelial carcinoma (or with squamous differentiation\u002Fsarcomatoid differentiation).\n  3. Moderate or severe hydronephrosis: Ipsilateral moderate or severe hydronephrosis due to tumor obstruction.\n  4. Large tumor size: Imaging measures maximum tumor diameter \\> 2 cm.\n  5. cN1: Imaging suggests regional lymph node short-axis diameter \\> 1 cm, and the investigator judges it to be resectable.\n* Presence of at least one measurable lesion according to RECIST v1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function meeting the following requirements (without use of any blood components or colony-stimulating factors within 14 days):\n\nBone marrow function: Neutrophils ≥ 1,500\u002Fmm³, Platelets ≥ 100,000\u002Fmm³, Hemoglobin ≥ 9 g\u002FdL (5.6 mmol\u002FL).\n\nRenal function: Serum creatinine ≤ 1.5 mg\u002FdL and\u002For Creatinine clearance ≥ 60 mL\u002Fmin.\n\nLiver function: Total bilirubin ≤ 1.5 × ULN, AST \\& ALT ≤ 1.5 × ULN.\n\n* For women of childbearing potential (WOCBP): Must agree to use a highly effective medically approved contraceptive method during the treatment period and for 3 months after treatment ends. A negative serum or urine pregnancy test within 7 days before enrollment is required; must be non-lactating. For non-sterilized male patients: Must agree to use effective contraception with their partner during the treatment period and for 3 months after treatment ends.\n* Subject voluntarily joins the study, has good compliance, and agrees to undergo safety and survival follow-up.\n\nExclusion Criteria:\n\n* Previous receipt of any anti-tumor therapy for UTUC, including chemotherapy, radiotherapy, immunotherapy, or targeted therapy.\n* History or concurrent presence of muscle-invasive bladder urothelial carcinoma.\n* Preoperative imaging assesses regional lymph nodes as unresectable: lymph nodes fused into a massive conglomerate, or fully encasing the abdominal aorta\u002Finferior vena cava\u002Fpelvic vessels preventing safe separation.\n* Known bilateral UTUC or hereditary diseases that definitively increase the risk of contralateral upper tract tumors, such as Lynch Syndrome.\n* Diagnosis of other active malignancies within the past 5 years (except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix which have been cured and show no recurrence within 5 years).\n* Presence of any active autoimmune disease or history of autoimmune disease.\n* Current use of immunosuppressants for immunosuppressive purposes, continued within 2 weeks prior to enrollment.\n* Poorly controlled cardiac clinical symptoms or diseases.\n* Coagulation abnormalities or bleeding tendency.\n* Presence of specific active gastrointestinal conditions or uncontrolled tumor bleeding.\n* History of significant bleeding, hemoptysis, or thromboembolic events within specified timeframes.\n* Active infection or unexplained fever \\> 38.5°C during screening or before the first dose.\n* Occurrence of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to surgery.\n* History or current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, etc.\n* Congenital or acquired immunodeficiency.\n* Participation in another clinical study within 1 month prior to enrollment, or potential receipt of other systemic anti-tumor therapy during the study period.\n* Known history of psychotropic drug abuse, alcohol abuse, or drug use.\n* Inability or unwillingness to bear the out-of-pocket costs of examinations and treatments.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are:\n\nDo patients who receive standard surgery with LND live longer without their cancer returning? Is adding LND safe, and how does it affect surgery-related complications? Researchers will compare the group receiving standard surgery plus LND to the group receiving standard surgery alone to see if adding LND is more effective.\n\nParticipants will:\n\nBe randomly assigned to one of the two surgical groups. Undergo their assigned surgery and recover in the hospital. Attend regular follow-up visits for checkups and scans for 5 years to monitor for cancer recurrence, with the possibility of long-term follow-up extending to 10 years.",[27,28],"Upper Tract Urothelial Carcinoma","Lymph Node Dissection",[30,31,32,33,34],"Upper tract urothelial carcinoma (UTUC)","Template Lymph node dissection","Nephroureterectomy","High-risk neoplasm","Randomized Controlled Trial","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2025-09-01",{"date":43,"type":21},"2032-08-30",{"name":45,"class":46},"Tianjin Medical University Second Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100634221","comparison-of-serratus-posterior-superior-intercostal-plane-block-and-rhomboid-intercostal-block-in-patients-undergoing-breast-cancer-surgery-100634221","NCT07536867","Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block in Patients Undergoing Breast Cancer Surgery","Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block for Postoperative Analgesia Following Breast Cancer Surgery With Axillary Lymph Node Dissection: A Randomized Controlled Trial","SPSIP-RIB","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* ASA physical status I-III\n* Scheduled for elective breast cancer surgery with axillary lymph node dissection\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Ability to understand and use the patient-controlled analgesia (PCA) device\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Allergy to local anesthetics\n* Infection at the injection site\n* Coagulopathy or ongoing anticoagulant therapy\n* Chronic opioid use or opioid dependence\n* Severe hepatic or renal insufficiency\n* Pregnancy or breastfeeding\n* Cognitive impairment or inability to communicate pain scores\n* Body mass index (BMI) \\\u003C18 or \\>35 kg\u002Fm²","FEMALE","65 Years",{"count":59,"type":21},60,[24],"This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Rhomboid Intercostal Block in patients undergoing Breast Cancer Surgery With Axillary Lymph Node Dissection. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire.",[63,28,64,65],"Breast Cancer","Postoperative Pain","Mastectomy",[67,68,69,70,71],"SPSIP","rhomboid intercostal block","regional anesthesia","axillary dissection","serratus posterior superior intercostal plane block","NOT_YET_RECRUITING","2026-05-07",{"date":75,"type":39},"2026-05-11",{"date":77,"type":21},"2026-08-30",{"date":79,"type":21},"2027-09-30",{"name":81,"class":46},"Antalya City Hospital",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100624221","phase-3-the-value-of-near-infrared-fluorescence-imaging-in-the-protection-of-the-recurrent-laryngeal-nerve-during-minimally-invasive-esophagectomy-100624221","NCT07406815","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy：A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years at the time of diagnosis (excluding 18 and 75);\n* Preoperative biopsy pathology confirming esophageal cancer;\n* Undergoing elective thoracoscopic esophageal cancer radical surgery with intraoperative anastomosis;\n* Tolerable heart, lung, liver, and kidney function for surgery;\n* Patients and their families are able to understand and willing to participate in this clinical study, and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Allergy to ICG or iodine;\n* History of neck or thoracic surgery;\n* Patients requiring emergency surgery;\n* Tumors involving adjacent organs necessitating combined organ resection;\n* Patients with tumor recurrence or distant metastasis;\n* Participation in or having participated in other clinical trials within 4 weeks prior to selection;\n* History of severe mental illness;\n* Pregnant or lactating women;\n* Patients with other conditions deemed unsuitable for participation by the investigator;\n* Intraoperative conversion to open thoracotomy.\n* Patients who, after assessment or intraoperative exploration, cannot undergo the planned surgery;\n* Patients who voluntarily withdraw from the study;\n* Patients with concomitant non-neoplastic conditions that prevent them from continuing with the study protocol;\n* Patients who, after enrollment in the study, are unable to complete it due to other reasons.","75 Years",{"count":91,"type":21},144,[93],"PHASE3","The goal of this clinical trial is to learn whether the application of indocyanine green near-infrared imaging system can accurately locate the recurrent laryngeal nerve (RLN) during lymph node dissection in esophageal cancer radical surgery, thereby reducing the risk of RLN injury. The main questions it aims to answer are:\n\n1. Can preoperative intravenous administration of indocyanine green enable visualization of the RLN;\n2. Does performing RLN dissection guided by near-infrared imaging system reduce the probability of RLN injury, leading to better clearance of RLN lymph nodes and improved RLN protection rates? Researchers will compare whether indocyanine green was intravenously administered preoperatively to assess intraoperative RLN visualization. Participants in the study group will receive intravenous indocyanine green at a dose of 5mg\u002Fkg 24 hours before surgery. All patients will be monitored for RLN injury-related complications postoperatively, and RLN injury status will be objectively assessed via laryngoscopy one week post-operation.",[96,97,98,28],"Esophageal Cancer","Recurrent Laryngeal Nerve","ICG (Indocyanine Green)","2026-02-05",{"date":101,"type":39},"2026-02-12",{"date":103,"type":21},"2026-06-01",{"date":105,"type":21},"2028-06-01",{"name":107,"class":46},"Fujian Medical University Union Hospital",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100564884","selective-lymph-node-resection-for-invasive-non-small-cell-lung-cancer-with-the-ctr-of-05-1-and-the-diameter-of--2-cm-100564884","NCT06634979","Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm","Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm: a Prospective， Single-arm, Multi-center, Phase Ⅱ Trial","Inclusion Criteria:\n\n* Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;\n* Age 18-80 years at time of signing informed consent (including threshold);\n* ECOG score 0 or 1;\n* No previous surgery for lung cancer;\n* Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;\n* Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;\n* The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;\n* Patients with clinical stage T1N0M0 surgically resectable;\n* Primary treatment without radiotherapy or chemotherapy.\n\nExclusion Criteria:\n\n* T1N0M0 with a clinical stage other than 0.5 \\\u003C CTR \\\u003C 1 and a diameter of ≤ 2 cm;\n* Inability to perform complete surgical resection;\n* cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;\n* Previous surgery for lung cancer;\n* Patients who have received radiotherapy or chemotherapy for non-primary treatment.","80 Years",{"count":117,"type":21},684,[24],"The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \\\u003C CTR \\\u003C 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \\\u003C CTR \\\u003C 1 and ≤ 2 cm in diameter.",[121,28],"Lung Cancer (NSCLC)",[123],"Selective lymph node dissection","2025-08-07",{"date":126,"type":39},"2025-08-12",{"date":128,"type":39},"2024-05-01",{"date":130,"type":21},"2029-05-01",{"name":132,"class":46},"Fudan University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":47},"100437223","phase-2-indocyanine-green-tracer-using-in-laparoscopic-distal-gastrectomy-for-early-gastric-cancer-100437223","NCT04973475","Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer","Prospective Clinical Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy With Lymph Node Dissection for Early Gastric Cancer","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy\n3. Clinical stage tumor T1 (cT1), N0\u002F+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition. Preoperative staging was made by conducting mandatory computed tomography (CT) scans and an optional endoscopic ultrasound\n4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations\n5. Tumor located in the lower third of the stomach, expected to receive radical distal gastrectomy\n6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)\n7. American Society of Anesthesiology score (ASA) class I, II, or III\n8. Written informed consent\n\nExclusion Criteria:\n\n1. Women during pregnancy or breast-feeding\n2. Severe mental disorder\n3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)\n4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection\n5. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging\n6. History of other malignant disease within past five years\n7. History of previous neoadjuvant chemotherapy or radiotherapy\n8. History of unstable angina or myocardial infarction within past six months\n9. History of cerebrovascular accident within past six months\n10. History of continuous systematic administration of corticosteroids within one month\n11. Requirement of simultaneous surgery for other disease\n12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer\n13. Forced expiratory volume in 1 second (FEV1)\\\u003C50% of predicted values\n14. Rejection of laparoscopic resection\n15. Preoperatively confirmed tumors invading the dentate line or duodenum\n16. History of allergy to iodine agents\n17. Tumor located in the upper third of the stomach, expected to receive radical total gastrectomy",{"count":141,"type":21},180,[143],"PHASE2","This study aims to explore the value of indocyanine green (ICG) in laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer.The patients with early gastric adenocarcinoma (cT1, N-\u002F+, M0) will be studied.",[146,147,28],"Early Gastric Cancer","Indocyanine Green",[149,150,151,28],"Stomach Neoplasms","Indocyanine Green Tracer","Laparoscopic Distal Gastrectomy","2021-07-13",{"date":154,"type":39},"2021-07-22",{"date":156,"type":21},"2021-07",{"date":158,"type":21},"2026-07",{"name":160,"class":46},"Fujian Medical University"]